Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

RGNX vs LXRX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

RGNX Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 3–5 Matrix Metrics)

RGNX Overall Winner 6-Pillar Tally: RGNX 5 – 1 LXRX Matrix Metrics: RGNX 3 – 5 LXRX

As of Nov 16, 2026, REGENXBIO Inc. (RGNX) is the stronger overall head-to-head candidate over Lexicon Pharmaceuticals, Inc. (LXRX) in the Tradestie Institutional Equity Comparison Engine, winning 3–5 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). RGNX carries a Unified Composite Score of 45.3/100 (HOLD) at $7.47 (N/M Forward P/E, -120.4% operating margin), whereas LXRX carries 38.7/100 (SELL) at $1.75 (N/M Forward P/E, -147.4% operating margin).

  • Growth vs. Quality Trade-Off: RGNX earns the overall head-to-head edge with a stronger Unified Composite Score (45.3/100 HOLD vs. LXRX 38.7/100 SELL) and 1.81β · 76% Vol risk profile, whereas LXRX leads top-line expansion (-20.7% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: RGNX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3); meanwhile LXRX is in a Breakdown options structure phase (RSI 54.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RGNX vs LXRX
RGNX NASDAQ Head-to-Head Winner
REGENXBIO Inc.
Biological Products, (No Disgnostic Substances)
$7.47
-2.23% 1D
Market Cap $500.9M
TTM Revenue $154M
Forward P/E N/M
Beta / 30D Vol 1.81β · 76% Vol
Unified Composite Score
45.3 / 100 HOLD
Tech 36.0 Fund 44.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -12.2%) with fading momentum, RSI 48
RSI-14: 48.3 · SMA20: $7.42 · SMA50: $7.63
LXRX NASDAQ
Lexicon Pharmaceuticals, Inc.
Pharmaceutical Preparations
$1.75
-2.51% 1D
Market Cap $810.3M
TTM Revenue $39M
Forward P/E N/M
Beta / 30D Vol 0.62β · 60% Vol
Unified Composite Score
38.7 / 100 SELL
Tech 5.0 Fund 33.0 Flow 65.0 Mom 44.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 54.2 · SMA20: $1.60 · SMA50: $1.76

6-Pillar Scorecard Institutional Category Breakdown (RGNX 5 – 1 LXRX)

Columns: Metric · RGNX · LXRX
1. Valuation Multiples RGNX
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio 0.26x N/M
EV / Revenue 3.1x 21.3x
2. Growth & Scale LXRX
Revenue Growth (YoY) -69.2% -20.7%
Earnings Growth (YoY) +0.0% -63.4%
TTM Revenue (USD) $154M $39M
Market Cap $500.9M $810.3M
3. Profitability & Quality RGNX
Gross Margin -64.5% 91.4%
Operating Margin -120.4% -147.4%
Net Profit Margin -113.9% -161.8%
Return on Equity (ROE) -113.2% -43.9%
4. Balance Sheet & Cash Flow RGNX
Cash Generation (TTM) -$155M -$49M
Cash Flow Margin -100.6% N/A
Net Cash / Leverage $29M Net Cash $9.5M Net Debt (0.33x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning RGNX
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 349.6% (52nd %ile) 78.4% (8th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Distribution ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat RGNX
OpEx & R&D Intensity 55.9% of Rev ($86M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RGNX (3) vs LXRX (5)
Institutional Metric RGNX LXRX Criterion Row Edge
Market Capitalization
Scale
$500.9M $810.3M Larger Scale LXRX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-69.2% -20.7% Higher Growth LXRX
Operating Margin (TTM)
Profitability
-120.4% -147.4% Higher Margin RGNX
Net Profit Margin
Profitability
-113.9% -161.8% Higher Margin RGNX
Return on Equity (ROE)
Capital Efficiency
-113.2% -43.9% Higher ROE LXRX
52-Week Range Position
Momentum
19% ($5–$16) 41% ($1–$3) Stronger Trend LXRX
Beta / 30D Volatility
Risk Regime
1.81β · 76% Vol 0.62β · 60% Vol Lower Realized Risk LXRX
Unified Institutional Score
Composite Signal
45.3 / 100 (HOLD) 38.7 / 100 (SELL) Higher Composite RGNX
Trailing 12M Revenue (USD)
Operating Scale
$154M $39M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-64.5% 91.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.26x PEG · 3.1x EV/Rev N/M PEG · 21.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$155M ($29M Net Cash) -$49M ($9.5M Net Debt (0.33x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon LXRX +6.93 pp
RGNX: +7.87% · LXRX: +14.8%
3M Horizon LXRX +4.63 pp
RGNX: -32.52% · LXRX: -27.89%
6M Horizon RGNX +50.67 pp
RGNX: +32.21% · LXRX: -18.46%
1Y Horizon LXRX +57.0 pp
RGNX: -35.82% · LXRX: +21.18%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period RGNX Revenue LXRX Revenue RGNX Op. Margin LXRX Op. Margin Margin Leader
FY2018 $220M $30M 40.3% -388.5% RGNX
FY2019 $40M $30M -422.9% 437.5% LXRX
FY2020 $150M $20M -77.1% -204.2% RGNX
FY2021 $470M N/A 34.0% N/A RGNX
FY2022 $110M N/A -233.2% N/A RGNX
FY2023 $90M $0M -297.1% -15473.0% RGNX
FY2024 $80M $10M -280.0% -3284.7% RGNX
FY2025 $170M $50M -94.6% -98.2% RGNX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RGNX BREAKDOWN
91d in phase · OBV ACCUMULATION
Current IV 349.6%
IV Percentile 52nd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact RGNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LXRX BREAKDOWN
98d in phase · OBV ACCUMULATION
Current IV 78.4%
IV Percentile 8th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact LXRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RGNX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $500.9M market capitalization and -120.4% operating margin.
OpEx & R&D Reinvestment 55.9% of Rev ($86M)
90D Engineering Disclosures 0 Published
LXRX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $810.3M market capitalization and -147.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ RGNX vs LXRX Key Questions & Quantitative Answers

As of Nov 16, 2026, REGENXBIO Inc. (RGNX) is the stronger overall head-to-head candidate over Lexicon Pharmaceuticals, Inc. (LXRX) in the Tradestie Institutional Equity Comparison Engine, winning 3–5 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). RGNX carries a Unified Composite Score of 45.3/100 (HOLD) at $7.47 (N/M Forward P/E, -120.4% operating margin), whereas LXRX carries 38.7/100 (SELL) at $1.75 (N/M Forward P/E, -147.4% operating margin). Growth vs. Quality Trade-Off: RGNX earns the overall head-to-head edge with a stronger Unified Composite Score (45.3/100 HOLD vs. LXRX 38.7/100 SELL) and 1.81β · 76% Vol risk profile, whereas LXRX leads top-line expansion (-20.7% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: RGNX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3); meanwhile LXRX is in a Breakdown options structure phase (RSI 54.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

LXRX leads the Growth & Scale pillar: RGNX posts -69.2% YoY revenue growth and +0.0% YoY earnings growth on $154M TTM revenue (-64.5% gross margin, -120.4% operating margin), compared with LXRX at -20.7% YoY revenue growth and -63.4% YoY earnings growth on $39M TTM revenue (91.4% gross margin, -147.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), RGNX cumulative revenue shifted -22.7% while LXRX shifted +66.7%. In operating R&D and SG&A reinvestment, RGNX deploys 55.9% of Rev ($86M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LXRX.

RGNX screens cheaper on headline valuation multiples. RGNX trades at N/M Forward P/E, N/M Trailing P/E, 0.26x PEG, and 3.1x EV/Revenue (-100.6% FCF margin), whereas LXRX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 21.3x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RGNX (-113.2% ROE) versus LXRX (-43.9% ROE) capital efficiency.

In options market volatility and institutional positioning, RGNX carries 349.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.81β · 76% Vol realized risk). By comparison, LXRX carries 78.4% implied volatility (8th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.62β · 60% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.